Sorafenib drug interactions | Litt's Drug Eruption and Reaction Database

Sorafenib comment watch save

TRADE NAME: Nexavar (Bayer)
INDICATIONS: Advanced renal cell carcinoma
CLASS: Angiogenesis inhibitor / antiangiogenic agent, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), RET (Rearranged during Transfection) kinase inhibitor, Tyrosine kinase inhibitor, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
HALF-LIFE: 25–48 hours

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Bevacizumab, Carbamazepine, Clozapine, Conivaptan, Coumarins, CYP3A4 inducers, Darunavir, Delavirdine, Dexamethasone, Digoxin, Docetaxel, Doxorubicin, Efavirenz, Indinavir, Irinotecan, Neomycin, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, St John's Wort, Telithromycin, Voriconazole, Warfarin

See adverse reactions attributed to class:
Angiogenesis inhibitor / antiangiogenic agent
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
RET (Rearranged during Transfection) kinase inhibitor
Tyrosine kinase inhibitor
Vascular endothelial growth factor (VEGF) inhibitor / antagonist

In combination with carboplatin and paclitaxel, Nexavar is contra-indicated in patients with squamous cell lung cancer.

Please login to view the rest of this drug profile.

Page last updated 05/01/2025

Litt's app available free to subscribers

Search drug eruptions and reactions data anytime, anywhere

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

Breast feeding

Geriatric

Pediatric